Table 2

Disease-specific summary statistics of significant PEA CSF biomarkers

CSF biomarkerPSP (n=54) mean (NPX)
SD		CBS (n=22) mean (NPX)
SD		MSA (n=38) mean (NPX)
SD		PD (n=37) mean (NPX)
SD		CON (n=34) mean (NPX)
SD
FGF-53.26*†
0.54		3.28*†
0.52		2.93*†§¶
0.58		3.60†
0.53		3.52†§¶
0.46
MSR12.11*
0.40		2.08*†
0.39		2.02*
0.48		1.95*
0.50		1.58†‡§¶
0.48
VWC24.78*
0.49		4.93
0.55		4.55*‡
0.54		5.13†
0.51		5.06†§
0.51
VEGF-A9.24*
0.46		9.34
0.54		8.98*‡
0.53		9.61†
0.46		9.48†§
0.55
ADAM227.64*‡
0.29		7.67
0.24		7.56*‡
0.26		7.84†§
0.25		7.78†§
0.26
DNER10.02*
0.15		10.00*
0.17		9.96*‡
0.16		10.11†
0.14		10.08†§¶
0.13
UNC5C2.14*
0.51		2.26
0.51		2.09*†
0.51		2.43†
0.43		2.46†§
0.47
ADAM233.00*
0.30		3.04
0.34		2.89*‡
0.33		3.21†
0.26		3.17†§
0.28
SPOCK17.15*†‡
0.29		7.12†
0.37		6.94*द
0.32		7.36†§
0.29		7.23†§
0.29
N2DL-24.13*
0.72		3.92*‡
0.71		3.90*‡
0.85		4.60†¶
0.74		4.52†§¶
0.86
FGF-194.53*†
0.55		4.70†
0.53		4.23*द
0.59		4.90†
0.51		4.79†§
0.54

  • Only statistically significant (p<0.05) differences are noted from logistic regression analyses.

  • *vs controls.

  • †vs MSA.

  • ‡vs PD.

  • §vs PSP.

  • ¶vs CBS.

  • CBS, corticobasal syndrome; CON, controls; CSF, cerebrospinal fluid; MSA, multiple system atrophy; NPX, normalised protein expression value; PD, Parkinson’s disease; PEA, proximity extension assay; PSP, progressive supranuclear palsy.